Literature DB >> 17376859

Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation.

Peter C Fusco1, Esmé K Farley, Chun-Hsien Huang, Samuel Moore, Francis Michon.   

Abstract

Previous studies with group C meningococcal polysaccharide-tetanus toxoid (GCMP-TT) conjugates had suggested that the GCMP O-acetyl group masked the protective epitope for group C meningococci through steric hindrance or altered conformations. For this report, we confirmed this phenomenon and performed comparative studies with group Y meningococcal polysaccharide (GYMP)-TT to determine whether it might extend to other serogroups. The de-O-acetylated (dOA) polysaccharides (PSs) resulted in higher serum bactericidal activities (SBA) towards the O-acetylated (OA) meningococcal strains from the respective serogroups. High-resolution H-nuclear magnetic resonance spectroscopy at 500 MHz and competitive inhibition serum bactericidal assays were used to characterize the nature of the protective epitope. In head-to-head comparisons with OA PSs as SBA inhibitors, the dOA PSs provided 10 to 1,000 times better inhibition for GCMP in human and mouse antisera and 6 to 13 times better inhibition for GYMP in mouse antisera, using OA strains in all assays. In addition, the SBA for OA strains was highly correlated with dOA PS-specific immunoglobulin G (r=0.72 to 0.98) for both GCMP and GYMP. The results suggest that there may be a generalized role for the O-acetyl group to provide an epitope of misdirected immunogenicity for meningococcal PS capsules, enabling escape from immune surveillance. In addition to greater chemical consistency, the dOA forms of GCMP and GYMP conjugate vaccines endow greater immunologic competence to the PSs, rendering them capable of eliciting higher levels of functional antibodies toward the protective epitopes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17376859      PMCID: PMC1865638          DOI: 10.1128/CVI.00009-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  51 in total

1.  Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England.

Authors:  M E Ramsay; N Andrews; E B Kaczmarski; E Miller
Journal:  Lancet       Date:  2001-01-20       Impact factor: 79.321

2.  Epidemics of meningococcal disease. African meningitis belt, 2001.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2001-09-14

Review 3.  Meningococcal disease.

Authors:  N E Rosenstein; B A Perkins; D S Stephens; T Popovic; J M Hughes
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

4.  Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults.

Authors:  P Richmond; D Goldblatt; P C Fusco; J D Fusco; I Heron; S Clark; R Borrow; F Michon
Journal:  Vaccine       Date:  1999-11-12       Impact factor: 3.641

5.  Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains.

Authors:  P Richmond; R Borrow; J Findlow; S Martin; C Thornton; K Cartwright; E Miller
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

6.  Structure activity studies on group C meningococcal polysaccharide-protein conjugate vaccines: effect of O-acetylation on the nature of the protective epitope.

Authors:  F Michon; C H Huang; E K Farley; L Hronowski; J Di; P C Fusco
Journal:  Dev Biol (Basel)       Date:  2000

7.  Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.

Authors:  P Richmond; R Borrow; D Goldblatt; J Findlow; S Martin; R Morris; K Cartwright; E Miller
Journal:  J Infect Dis       Date:  2000-11-14       Impact factor: 5.226

8.  Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story.

Authors:  E Miller; D Salisbury; M Ramsay
Journal:  Vaccine       Date:  2001-10-15       Impact factor: 3.641

9.  Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.

Authors:  R Borrow; N Andrews; D Goldblatt; E Miller
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

10.  Strucutres of the capsular polysaccharides of Neisseria meningitidis as determined by 13C-nuclear magnetic resonance spectroscopy.

Authors:  H J Jennings; A K Bhattacharjee; D R Bundle; C P Kenny; A Martin; I C Smith
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

View more
  23 in total

1.  The Pneumococcal Serotype 15C Capsule Is Partially O-Acetylated and Allows for Limited Evasion of 23-Valent Pneumococcal Polysaccharide Vaccine-Elicited Anti-Serotype 15B Antibodies.

Authors:  Brady L Spencer; Anukul T Shenoy; Carlos J Orihuela; Moon H Nahm
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

2.  Structural and kinetic characterizations of the polysialic acid O-acetyltransferase OatWY from Neisseria meningitidis.

Authors:  Ho Jun Lee; Bojana Rakić; Michel Gilbert; Warren W Wakarchuk; Stephen G Withers; Natalie C J Strynadka
Journal:  J Biol Chem       Date:  2009-06-12       Impact factor: 5.157

Review 3.  Regulation of capsule in Neisseria meningitidis.

Authors:  Yih-Ling Tzeng; Jennifer Thomas; David S Stephens
Journal:  Crit Rev Microbiol       Date:  2015-06-19       Impact factor: 7.624

4.  A semisynthetic Streptococcus pneumoniae serotype 8 glycoconjugate vaccine.

Authors:  Benjamin Schumann; Heung Sik Hahm; Sharavathi G Parameswarappa; Katrin Reppe; Annette Wahlbrink; Subramanian Govindan; Paulina Kaplonek; Liise-Anne Pirofski; Martin Witzenrath; Chakkumkal Anish; Claney L Pereira; Peter H Seeberger
Journal:  Sci Transl Med       Date:  2017-03-08       Impact factor: 17.956

5.  Antibodies to Staphylococcus aureus capsular polysaccharides 5 and 8 perform similarly in vitro but are functionally distinct in vivo.

Authors:  Bo Liu; Saeyoung Park; Christopher D Thompson; Xue Li; Jean C Lee
Journal:  Virulence       Date:  2016-12-09       Impact factor: 5.882

6.  Position of O-Acetylation within the Capsular Repeat Unit Impacts the Biological Properties of Pneumococcal Serotypes 33A and 33F.

Authors:  Brady L Spencer; Jamil S Saad; Anukul T Shenoy; Carlos J Orihuela; Moon H Nahm
Journal:  Infect Immun       Date:  2017-06-20       Impact factor: 3.441

7.  Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine.

Authors:  Ray Borrow; Nick Andrews; Helen Findlow; Pauline Waight; Joanna Southern; Annette Crowley-Luke; Lorraine Stapley; Anna England; Jamie Findlow; Elizabeth Miller
Journal:  Clin Vaccine Immunol       Date:  2009-11-11

8.  Epitope specificities of the group Y and W-135 polysaccharides of Neisseria meningitidis.

Authors:  Samuel L Moore; Catherine Uitz; Chang-Chun Ling; David R Bundle; Peter C Fusco; Francis Michon
Journal:  Clin Vaccine Immunol       Date:  2007-09-05

9.  Antibodies to Staphylococcus aureus serotype 8 capsular polysaccharide react with and protect against serotype 5 and 8 isolates.

Authors:  Saeyoung Park; Sabina Gerber; Jean C Lee
Journal:  Infect Immun       Date:  2014-09-22       Impact factor: 3.441

10.  Functional antibodies to the O-acetylated pneumococcal serotype 15B capsular polysaccharide have low cross-reactivities with serotype 15C.

Authors:  Gowrisankar Rajam; George M Carlone; Sandra Romero-Steiner
Journal:  Clin Vaccine Immunol       Date:  2007-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.